X.a

DRES syndrome - DRESS-like reaction

DRESS stands for 'Drug Rash, Eosinophilia, Systemic Symptoms or Syndrome'. Includes internal organ involvement (liver, bone marrow, kindney, lung, heart in the form of myocarditis (PMID 21658796)) and occasionally MOF/MODS. Respiratory involvement (in about 15% of the patients), is in the form of cough, dyspnea, wheezing, pleural effusion, pulmonary infiltrates or PIE. See also under eosinophilic pneumonia. A precise definition of the syndrome has been available since 1996 (Bocquet et al.). Earlier cases of 'Drug Hypersensitivity' in the literature likely represent authentic DRESS cases. Review and lists of causal drugs at PMID 21592453, 26354734. Reviews at PMID 23602182, 23602183, 25592341, 30140942, 32247873 Cardiac involvement: PMID 35160164
Last update : 01/01/1970
 

Causative drugs

85

Hydralazine

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH)
III.b III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.b - Pneumorenal syndrome (w/wo ANCAs)
III.d III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.d - Alveolar hemorrhage, diffuse (ANCA-positive/-related)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
V.i V - Pleural and/or pericardial involvement
V.i - Pleuritis (can cause chest pain)
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
VI.d VI - Pulmonary vasculopathies
VI.d - Pulmonary vasculitis or capillaritis
VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death)
VIII.c VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
VIII.h VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.h - Vocal cord dysfunction, adduction, closure, injury
X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction
X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)
X.o X - Systemic/Distant conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet syndrome)
X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive
X.ak X - Systemic/Distant conditions, syndromes and reactions
X.ak - Dual MPO-/PR3-ANCA systemic disease/vasculitis
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XII.k XII - Cardiovascular involvement / toxicity
XII.k - Constrictive pericarditis - Pericardial thickening
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
2

Imatinib

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening
V.i V - Pleural and/or pericardial involvement
V.i - Pleuritis (can cause chest pain)
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction
X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS)
X.r X - Systemic/Distant conditions, syndromes and reactions
X.r - Fluid retention
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XIII.g XIII - Neoplastic conditions
XIII.g - Lymphomatoid granulomatosis (pulmonary, endothoracic)
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.n XV - Pathology
XV.n - Path: Pulmonary alveolar proteinosis pattern (PAP pattern)
XV.ch XV - Pathology
XV.ch - Path: Organizing fibrinous pleuritis (OFP)
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection/superinfection
XVII.o XVII - Infections & related conditions
XVII.o - Nocardia pulmonary/systemic infection
XVII.w XVII - Infections & related conditions
XVII.w - Hypogammaglobulinemia - Antibody deficiency
1

Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id)
I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis
I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis
I.aj I - Interstitial/parenchymal lung disease
I.aj - Shrinking lung syndrome
I.ax I - Interstitial/parenchymal lung disease
I.ax - Chronic pneumonitis
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic
III.m III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.m - Coagulopathy
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)
IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc, XVx)
IV.y IV - Airway involvement
IV.y - Eosinophilic airway disease (asthma, bronchitis, bronchiolitis)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VIII.t VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.t - Vocal cord paresis/paralysis
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis - Myasthenic-like syndrome
IX.ab IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ab - Guillain-Barré (or GB-like) syndrome (w/wo ARF)
IX.ac IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ac - Myositis of the respiratory muscles (May lead to respiratory muscle paralysis)
X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction
X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS)
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal)
X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
X.h X - Systemic/Distant conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba)
X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic)
X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)
X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive
X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
X.am X - Systemic/Distant conditions, syndromes and reactions
X.am - Immune-related adverse effect/toxicity
X.an X - Systemic/Distant conditions, syndromes and reactions
X.an - Cytokine release syndrome - Cytokine storm
X.aw X - Systemic/Distant conditions, syndromes and reactions
X.aw - Connective tissue disease
X.ay X - Systemic/Distant conditions, syndromes and reactions
X.ay - Polymyalgia rheumatica
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XI.y XI - Miscellaneous
XI.y - Adrenal suppression
XI.ag XI - Miscellaneous
XI.ag - Vertebral compression fracture
XI.au XI - Miscellaneous
XI.au - Graft vs. host disease in transplant recipients
XI.av XI - Miscellaneous
XI.av - Deterioration of graft function in SOT recipients
XI.ba XI - Miscellaneous
XI.ba - Nonrespiratory AE of interest
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant)
XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Cardiovascular collapse - Cardiogenic shock - Hypotension
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity
XII.ax XII - Cardiovascular involvement / toxicity
XII.ax - Necrotizing myocarditis (w/o evidence for CAD)
XII.ba XII - Cardiovascular involvement / toxicity
XII.ba - Sudden cardiac death
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.l XV - Pathology
XV.l - Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)
XV.v XV - Pathology
XV.v - Path: Micronodular organizing pneumonia/BOOP
XV.x XV - Pathology
XV.x - Path: Acute/subacute bronchiolitis (see also IVc, IVi)
XV.ba XV - Pathology
XV.ba - Path: Granulomatous lymphadenopathy
XV.co XV - Pathology
XV.co - Path: Foamy inclusions in alveolar macrophages and/or in other lung cells
XV.cp XV - Pathology
XV.cp - Path: Pneumocyte vacuolization
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVI.v XVI - Imaging
XVI.v - Imaging: Centrilobular micronodules (can be diffuse)
XVI.bh XVI - Imaging
XVI.bh - Imaging: F18-PET scan positive lympadenopathy
XVI.bt XVI - Imaging
XVI.bt - Imaging: A subsolid lung nodule or nodules
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo
XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia
XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary)
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils
XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
1

Infliximab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism
VI.d VI - Pulmonary vasculopathies
VI.d - Pulmonary vasculitis or capillaritis
X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction
X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal)
X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
X.h X - Systemic/Distant conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba)
X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic)
X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive
X.ah X - Systemic/Distant conditions, syndromes and reactions
X.ah - Granulomatosis with polyangiitis (typically ANCA pos.) - GPA flare
X.ar X - Systemic/Distant conditions, syndromes and reactions
X.ar - Relapse/flare/onset of Crohn's disease
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant)
XII.br XII - Cardiovascular involvement / toxicity
XII.br - Right ventricular thrombus/thrombosis
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.cs XV - Pathology
XV.cs - Path: Pleural granulomas
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)
XVII.d XVII - Infections & related conditions
XVII.d - Pneumocystis jiroveci pulmonary colonization
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection/superinfection
XVII.n XVII - Infections & related conditions
XVII.n - Legionella pneumophila pneumonia
XVII.o XVII - Infections & related conditions
XVII.o - Nocardia pulmonary/systemic infection
XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia
XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary)
XVII.y XVII - Infections & related conditions
XVII.y - Cryptococcus pulmonary and/or systemic infection
XVII.z XVII - Infections & related conditions
XVII.z - Histoplamosis (reactivation)
XVII.ac XVII - Infections & related conditions
XVII.ac - Actinomycosis
1

Ipilimumab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy
IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis
IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis - Myasthenic-like syndrome
IX.ab IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ab - Guillain-Barré (or GB-like) syndrome (w/wo ARF)
X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction
X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba)
X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic)
X.l X - Systemic/Distant conditions, syndromes and reactions
X.l - Systemic granulomatosis other than Xk
X.o X - Systemic/Distant conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet syndrome)
X.am X - Systemic/Distant conditions, syndromes and reactions
X.am - Immune-related adverse effect/toxicity
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant)
XII.az XII - Cardiovascular involvement / toxicity
XII.az - Fulminant myocarditis (See also under XIId)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.ci XV - Pathology
XV.ci - Path: Fibrinous pericarditis
XVI.bh XVI - Imaging
XVI.bh - Imaging: F18-PET scan positive lympadenopathy
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
1

Leflunomide

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP)
I.q I - Interstitial/parenchymal lung disease
I.q - Pulmonary nodulosis
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
I.z I - Interstitial/parenchymal lung disease
I.z - An area or areas of consolidation
IV.d IV - Airway involvement
IV.d - Cough (lone)
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension
X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
1

Lenalidomide

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH)
IV.d IV - Airway involvement
IV.d - Cough (lone)
VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism
X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction
X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS)
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant)
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XVII.j XVII - Infections & related conditions
XVII.j - Mucormycosis (pulmonary, tracheobronchial or systemic)
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils
1

Mesalazine-Mesalamine-5-aminosalicylic acid-5-ASA

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)
IV.j IV - Airway involvement
IV.j - Bronchiolitis (a clinical-imaging pattern suggestive of)
IV.k IV - Airway involvement
IV.k - Bronchiectasis
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction
XII.h XII - Cardiovascular involvement / toxicity
XII.h - Eosinophilic myocarditis
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Cardiovascular collapse - Cardiogenic shock - Hypotension
XII.q XII - Cardiovascular involvement / toxicity
XII.q - Pericarditis (see also under XIIc)
XII.bf XII - Cardiovascular involvement / toxicity
XII.bf - Myopericarditis (see under XIIc/d/g)
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.z XV - Pathology
XV.z - Path: Obliterative (constrictive) bronchiolitis (see also IVc, IVn)
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVI.ay XVI - Imaging
XVI.ay - Imaging: Asymmetrical, predominantly unilateral involvement
XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
1

Minocycline

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.aj I - Interstitial/parenchymal lung disease
I.aj - Shrinking lung syndrome
II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
IV.d IV - Airway involvement
IV.d - Cough (lone)
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction
X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal)
X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)
X.o X - Systemic/Distant conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet syndrome)
X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive
X.v X - Systemic/Distant conditions, syndromes and reactions
X.v - Systemic eosinophilic syndrome w/wo vasculitis (see also Xa)
X.aj X - Systemic/Distant conditions, syndromes and reactions
X.aj - Polyarteritis nodosa-like condition
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade)
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis (can be fulminant)
XII.as XII - Cardiovascular involvement / toxicity
XII.as - Giant cell myocarditis
XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.ac XV - Pathology
XV.ac - Path: Pulmonary vasculitis other than capillaritis
XV.ad XV - Pathology
XV.ad - Path: Eosinophilic vasculitis
XV.af XV - Pathology
XV.af - Path: Granulomatous pulmonary vasculitis
XV.cj XV - Pathology
XV.cj - Path: Brownish macrophages in airspaces (airways - alveoli)
XVI.e XVI - Imaging
XVI.e - Imaging: Pulmonary opacities with a subpleural distribution
XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils
XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
1

Nitrofurantoin

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.r I - Interstitial/parenchymal lung disease
I.r - An imaging pattern consistent with DIP
I.ax I - Interstitial/parenchymal lung disease
I.ax - Chronic pneumonitis
II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury
II.j II - Pulmonary edema - Acute lung injury - ARDS
II.j - Transient pulmonary opacities/infiltrates (see also under Iav)
III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma
IV.ae IV - Airway involvement
IV.ae - Tracheobronchitis-like clinical pattern
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
V.i V - Pleural and/or pericardial involvement
V.i - Pleuritis (can cause chest pain)
VI.d VI - Pulmonary vasculopathies
VI.d - Pulmonary vasculitis or capillaritis
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VIII.b VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.b - Hematoma of/around central airway wall potentially causing UAO
IX.i IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.i - Respiratory arrest - Apnea
X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction
X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal)
X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive
XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent
XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain
XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib)
XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern
XV.j XV - Pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern)
XV.k XV - Pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern)
XV.x XV - Pathology
XV.x - Path: Acute/subacute bronchiolitis (see also IVc, IVi)
XV.ac XV - Pathology
XV.ac - Path: Pulmonary vasculitis other than capillaritis
XV.af XV - Pathology
XV.af - Path: Granulomatous pulmonary vasculitis
XV.bi XV - Pathology
XV.bi - Path: Giant-cell interstitial pneumonia (GIP)-pattern
XV.bl XV - Pathology
XV.bl - Path: Resolving alveolar damage
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing
XVI.f XVI - Imaging
XVI.f - Imaging: Bibasilar opacities/shadowing
XVI.l XVI - Imaging
XVI.l - Imaging: Peribronchovascular areas of consolidation
XVI.bc XVI - Imaging
XVI.bc - Imaging: Intrathoracic lymph node enlargement
XVI.bp XVI - Imaging
XVI.bp - Imaging: Reverse ventilation-perfusion mismatch
1